-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In advanced breast cancer with a positive estrogen receptor and a HER2-negative body, acquired resistance to aromatase inhibitors usually results from subclones of ESR1 mutations that may be sensitive
This randomized, open-label Phase 3 clinical trial enrolled patients aged 18 years or older with ECOG performance status of 0-2 points, positive estrogen receptors, and HER2-negative advanced breast cancer to detect the rise of
From 22 March 2017 to 31 January 2019, a total of 1017 patients were included, of whom 279 (27%) experienced an increase in bESR1 mutation, 172 (17%) were randomly assigned to two groups: 88 were changed to flovistan + pabocinib treatment, and 84 continued treatment with the original regimen
The most common ≥grade 3 hematologic adverse events were neutropenia (70.
In summary, the results of the study show that early targeted therapy bESR1 mutation can bring significant clinical benefits
Original Source:
Francois-Clement Bidard, et al.
